Gastroenterology · Proton Pump InhibitorRegulatory Approvalcommercialmid-term

FDA Accepts ANDA for Esomeprazole Magnesium by Marksans Pharma

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Marksans Pharma2 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/19/2026, 12:32:11 PM

Assessment confidence: 61% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of Marksans Pharma's ANDA for Esomeprazole Magnesium introduces a new generic competitor into the proton pump inhibitor market. This could significantly affect pricing and market share dynamics for existing esomeprazole products, necessitating strategic adjustments by current market players. Regulatory context from FDA (FDA AP — OMEPRAZOLE MAGNESIUM (SUPPL)) supports the near-term read. Assessment grounded in 20 ranked evidence items (7 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this new generic entry on market share and pricing strategies for existing esomeprazole products. The strongest clinical anchor is Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor and an Aromata (ClinicalTrials.gov), sponsor/company relevance (novartis). In Gastroenterology · Proton Pump Inhibitor, 7 regulatory and 2 competitive items passed relevance filtering for Marksans Pharma.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Accepts BLA for IMMGOLIS (GOLIMUMAB-SLDI) by Accord Biopharma. This acceptance may increase competition in the proton pump inhibitor market, potentially impacting existing brands.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — OMEPRAZOLE MAGNESIUM (SUPPL) (FDA). Entity match (marksans pharma); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, PMDA. While the ANDA has been accepted, there are no immediate regulatory compliance issues; however, ongoing monitoring of the approval timeline is necessary.

Key Opportunities

The entry of a generic version may lead to price erosion and increased competition, impacting revenue for established brands in the proton pump inhibitor category.
Upside for Marksans Pharma may improve if Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor and an Aromata (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Marksans Pharma may improve if A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Marksans Pharma may improve if An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Marksans Pharma may improve if Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease (ClinicalTrials.gov) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor the approval timeline and any potential market entry dates for Marksans Pharma's product.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — OMEPRAZOLE MAGNESIUM (SUPPL)
FDAhigh relevance
Entity match (marksans pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MAGNESIUM SULFATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — OMEPRAZOLE MAGNESIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
Internet Pharmacy Warning Letters
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
[YAKKYOKUKATA]Press Release regarding international activities related to Pharmacopoeia posted
PMDAmedium relevance
Moderate corpus alignment
FDA document
View source

Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor and an Aromata
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease Patients
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Accepts BLA for IMMGOLIS (GOLIMUMAB-SLDI) by Accord Biopharma
Humanexa Signalsmedium relevance
Moderate corpus alignment

Self-perceived learning outcomes of academic detailing discussing rational therapy with proton pump inhibitors among general practitioners in Norway.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Discovery of azaindole/indole-fused pyrimidine tetracyclic scaffolds as novel potent CDK7 inhibitors.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and drug survival after transitioning to IL-17 inhibitors in patients with psoriasis who did not respond to IL-23 inhibitors: analysis from the BIOREP registry.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Marksans Pharma
Esomeprazole

Commercial impact

medium

The entry of a generic version may lead to price erosion and increased competition, impacting revenue for established brands in the proton pump inhibitor category.

Regulatory impact

low

While the ANDA has been accepted, there are no immediate regulatory compliance issues; however, ongoing monitoring of the approval timeline is necessary.

What to watch

Monitor the approval timeline and any potential market entry dates for Marksans Pharma's product.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.